Table 1.

Overview over the transition probabilities

	To ... (M: Mezavant cohort; A: Asacol cohort)
From ...	1st line	1st line increased dosage	2nd line	Failure/relapse	Surgery	Post surgery	Remission	Death
Active UC: 1st line		M: 59.5% A: 67.4%					M: 40.5% A: 32.6%	0.0%**
Active UC: 1st line increased dosage			M: 38.5% A: 39.0%				M: 61.5% A: 60.0%	0.0%**
Active UC: 2nd line				M: 32.0% A: 32.0%			M: 68.0% A: 68.0%	0.0%**
Active UC: Failure/relapse					M: 25.8% A: 25.8%		M: 74.2% A: 74.2%	0.0%**
Surgery						M: 97.9% A: 97.9%		M: 2.1% A: 2.1%
Post surgery						M: 100.0% A: 100.0%		0.0%**
Remission	M: 6.5%* A: 9.2%*						M: 93.5% A: 90.8%	0.0%**
Death								M: 100.0% A: 100.0%

* This figure decreases as time spent in remission decreases the risk of active episodes [14,15]

** The overall cause mortality data [16] (dependent on the age cohort) is below 0.05% and is therefore displayed in the table as 0.0%.